...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Peptides: An International Journal >Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.
【24h】

Pituitary adenylate cyclase-activating peptide (PACAP): assessment of dipeptidyl peptidase IV degradation, insulin-releasing activity and antidiabetic potential.

机译：垂体腺苷酸环化酶激活肽（PACAP）：评估二肽基肽酶IV降解，胰岛素释放活性和抗糖尿病潜力。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pituitary adenylate cyclase-activating peptide (PACAP) is a member of the glucagon family of peptides. Like other members, most notably glucagon-like peptide-1 (GLP-1), PACAP is rapidly degraded by dipeptidylpeptidase IV (DPP IV). This study investigated how degradation by DPP IV affected the insulinotropic activity of PACAP, and whether PACAP exerted acute antihyperglycemic properties in normal or ob/ob mice. DPP IV degradation of PACAP(1-27) over 18 h led to the formation of PACAP(3-27), PACAP(5-27) and ultimately PACAP(6-27). In contrast to 1.4-1.8-fold concentration-dependent stimulation of insulin secretion by PACAP(1-27), these peptide fragments lacked insulinotropic activity. While PACAP(1-27) and PACAP(1-38) generated significant insulin responses when given alone or together with glucose in ob/ob and normal mice, they also elevated plasma glucose. These actions were eliminated following degradation of the peptide by incubation with DPP IV. The hyperglycemic effects may be explained at least partly by a potent glucagon-releasing action in ob/ob and normal mice. In conclusion, PACAP is inactivated by DPP IV and despite insulin-releasing effects, its actions on glucagon secretion and glucose homeostasis do not make it a good therapeutic tool for the treatment of type 2 diabetes.
机译：垂体腺苷酸环化酶激活肽（PACAP）是胰高血糖素肽家族的成员。像其他成员一样，最著名的是胰高血糖素样肽1（GLP-1），PACAP被二肽基肽酶IV（DPP IV）迅速降解。这项研究调查了DPP IV的降解如何影响PACAP的促胰岛素活性，以及​​PACAP是否在正常或ob / ob小鼠中发挥了急性降血糖作用。 DCAP IV在18小时内降解了PACAP（1-27），导致形成了PACAP（3-27），PACAP（5-27），最终形成了PACAP（6-27）。与PACAP（1-27）对胰岛素分泌的1.4-1.8倍浓度依赖性刺激相反，这些肽片段缺乏促胰岛素活性。当在ob / ob和正常小鼠中单独或与葡萄糖一起使用时，PACAP（1-27）和PACAP（1-38）会产生明显的胰岛素反应，但它们也会升高血浆葡萄糖。通过与DPP IV孵育，在肽降解后消除了这些作用。高血糖作用可以至少部分通过在ob / ob和正常小鼠中有效的胰高血糖素释放作用来解释。总之，PACAP被DPP IV灭活，尽管有胰岛素释放作用，但它对胰高血糖素分泌和葡萄糖稳态的作用并不使其成为治疗2型糖尿病的良好治疗工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号